Processing...
Processing...
Inmagic
®
Presto
Version 5.5 Build 151
Inmagic
®
Presto
Copyright © 2005-2021 by Lucidea Technologies Corp., Richmond BC Canada. All rights reserved.
Inmagic® and the Inmagic logo are registered trademarks of Lucidea Technologies Corp.
Unauthorized duplication or distribution is prohibited.
Other brand and product names are trademarks or registered trademarks of their respective holders. Use of any other product name does not imply endorsement of that product by Inmagic.
Third-party Licenses
Processing...
Processing...
Title
Administration intraveineuse de sécrétine dans le traitement des troubles du spectre autistique (TSA)
Subtitle
Intravenous Secretin for Autism Spectrum Disorders (ASD)
Author
Katrina Williams; John A. Wray; Danielle M. Wheeler
Summary
This online article, in French, summarizes a research review conducted to determine whether intravenous infusion of secretin, a gastrointestinal hormone, is an effective treatment for autism. Findings consistently indicated that secretin was not associated with reductions in autism symptoms. The authors therefore suggest that secretin should not be recommended or administered as an autism treatment.
This resource is available in English, Croatian, French, and Spanish.
Cochrane is a "global independent network of researchers, professionals, patients, carers, and people interested in health." [Website] The network reviews evidence about health treatments.
Language
French
Subjects
Therapies
Publisher
Cochrane
DateModified
12/30/2022 7:36 PM EST